What is Lorviqua and what is it used for?
Lorviqua contains the active substance lorlatinib, a medicine that is used for treatment of adults with advanced stages of a form of lung cancer called non-small cell lung cancer (NSCLC). Lorviqua belongs to the group of medicines that inhibit an enzyme called anaplastic lymphoma kinase (ALK). Lorviqua is only given to patients who have an alteration in the ALK gene.

Lorviqua can be prescribed for you if:

• you have not been previously treated with an ALK inhibitor;
• you have been previously treated with an ALK inhibitor

The medicine can only be obtained with a prescription.


Reference Information
If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for Lorviqua visit the electronic Medicines Compendium (eMC).

▼ This medicine is subject to additional monitoring.

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.

If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.